<DOC>
	<DOCNO>NCT01796964</DOCNO>
	<brief_summary>The purpose study compare efficacy safety ESBA1008 versus EYLEA® treatment exudative age-related macular degeneration .</brief_summary>
	<brief_title>Efficacy Safety Study ESBA1008 Versus EYLEA®</brief_title>
	<detailed_description>This study consist 16 visit ( Screening , Baseline [ Day 0 ] , 14 post-baseline assessment visit ) occur 4-week interval Week 56 . Enrolled subject randomize 1:1 receive ESBA1008 EYLEA . All subject receive active intravitreal ( IVT ) injection baseline 2 additional loading dos assign investigational product 4-week interval ( ie , Weeks 4 8 ) receive injection 8-weeks interval Weeks 16 , 24 , 32 . Subjects ESBA1008 group also receive injection Week 44 , subject EYLEA group also receive injection Weeks 40 48 . To maintain study masking , subject ESBA1008 group receive sham injection Weeks 40 48 ( subject EYLEA group receive active injection ) , subject EYLEA group receive sham injection Week 44 ( subject ESBA1008 group receive active injection ) . All subject follow Week 56 . Week 40 visit end assessment period 8-week treatment cycle .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Give write informed consent ; able make require study visit follow instruction . Diagnosis wet agerelated macular degeneration , specify protocol . Bestcorrected visual acuity ( BCVA ) specify protocol Other protocolspecified inclusion criterion may apply . Either eye : Any active ocular periocular infection active intraocular inflammation . Study eye : Any approved investigational treatment exudative AMD vitamin supplement . Study eye : Any current history macular retinal disease exudative AMD . Study eye : Any concurrent intraocular condition , opinion Investigator , could require medical surgical intervention course study prevent treat vision loss , limit potential gain visual acuity investigational product . Study eye : Uncontrolled glaucoma . Study eye : Any ocular disease , opinion Investigator , could compromise visual acuity . Study eye : History eye surgery , specify protocol . Study eye : Use corticosteroid , specify protocol . Any medical condition , opinion Investigator , would preclude schedule study visit , completion study safe administration investigational product . Any screen laboratory result , opinion Investigator , would make patient unsuitable study participation . History hypersensitivity component use study , assess Investigator . Women childbearing potential : Lactating , pregnant , plan become pregnant , use adequate birth control , specify protocol . Participation investigational drug device study within time period specify protocol . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Wet</keyword>
	<keyword>Exudative</keyword>
	<keyword>AMD</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Retina</keyword>
</DOC>